Srikanth Sola - Helix BioPharma Chief Officer
| HBP Stock | CAD 0.84 0.02 2.44% |
Executive
Srikanth Sola is Chief Officer of Helix BioPharma Corp
| Address | 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3 |
| Phone | 905-841-2300 |
| Web | https://www.helixbiopharma.com |
Helix BioPharma Management Efficiency
The company has return on total asset (ROA) of (4.5865) % which means that it has lost $4.5865 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (22.2062) %, meaning that it generated substantial loss on money invested by shareholders. Helix BioPharma's management efficiency ratios could be used to measure how well Helix BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Helix BioPharma's Return On Capital Employed is very stable compared to the past year. As of the 27th of November 2024, Return On Equity is likely to grow to 108.08, though Return On Tangible Assets are likely to grow to (5.91). At this time, Helix BioPharma's Debt To Assets are very stable compared to the past year. As of the 27th of November 2024, Asset Turnover is likely to grow to 0.53, while Total Assets are likely to drop about 1.4 M.Similar Executives
| Found 10 records | EXECUTIVE Age | ||
| RN BSN | Oncolytics Biotech | N/A | |
| Christopher Lobb | Microbix Biosystems | N/A | |
| Wayne MBA | Oncolytics Biotech | 69 | |
| Andres Gutierrez | Oncolytics Biotech | 58 | |
| BBA FCA | Oncolytics Biotech | N/A | |
| H MSc | Theratechnologies | 60 | |
| PMP PEng | Oncolytics Biotech | N/A | |
| LLB LLM | Theratechnologies | 56 | |
| BBA CM | Oncolytics Biotech | N/A | |
| Amy Levin | Oncolytics Biotech | N/A | |
Management Performance
| Return On Equity | -22.21 | ||||
| Return On Asset | -4.59 |
Helix BioPharma Corp Leadership Team
Elected by the shareholders, the Helix BioPharma's board of directors comprises two types of representatives: Helix BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Helix. The board's role is to monitor Helix BioPharma's management team and ensure that shareholders' interests are well served. Helix BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Helix BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namrata Malhotra, Corporate Secretary | ||
| Jacek Antas, Chairman CEO | ||
| Artur Gabor, CEO Chairman | ||
| Dr MA, Head RD | ||
| FCA FCA, CFO Secretary | ||
| Srikanth Sola, Chief Officer | ||
| Christof Boehler, Chief Officer | ||
| MBA MBA, Chief Officer |
Helix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Helix BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.82 | GOOG | Alphabet CDR | PairCorr |
| 0.81 | TSLA | Tesla Inc CDR | PairCorr |
| 0.79 | NVDA | NVIDIA CDR | PairCorr |
| 0.76 | VISA | Visa Inc CDR | PairCorr |
| 0.73 | INTC | INTEL CDR | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.